Genetic testing startup Sequencing wants to drive more insights into rare and chronic diseases — not by partnering with Big Pharma, as rivals like 23andMe have done, but by more comprehensively scanning the genome.
Why it matters: The Los Angeles-based startup raised $5 million in seed funding led by Lerer Hippeau, bringing total funding to $7 million, CEO Brandon Colby tells Axios exclusively. The capital will fuel acceleration of its whole genome sequencing (WGS) tech offering.
